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Introduction
Monoclonal antibodies (mAbs) have demonstrated utility in can-
cer research and treatment because of their exquisite specificity 
and relatively manageable side effects. However, antibody-based 
therapeutics have limited efficacy as single agents and thus are 
frequently used as an adjunct to chemotherapy. In such combi-
nation regimens, efficacy is limited by the toxicity associated to 
chemotherapy. The next generation of antibody-based therapy 
will involve the use of mAbs armed with potent cytotoxic drugs, 
radioisotopes and toxins for tumor-specific intracellular delivery. 
Based on their specificity and potency, antibody drug conju-
gates (ADCs) may enhance currently available chemotherapeutic 
approaches and at some point even obviate the need for systemic 
chemotherapy.
Among B-cell-specific antigens, CD22 is an ideal target 
for ADC therapy because: (1) it is broadly expressed by B-cell 
malignancies, (2) it undergoes rapid internalization following 
antibody binding and (3) it is not expressed by stem cell pre-
cursors, allowing for the regeneration of normal B cells follow-
ing ADC-based therapy. In line with this, at least 3 different 
CD22-targeted ADCs are under clinical investigation.1–3 CD22 
is a 140 kDa sialo-adhesion protein specifically expressed by nor-
mal and malignant B cells, and appears to be involved in the 
regulation of B-cell function and survival.4 CD22 expression has 
been observed in 60–80% of B-cell malignancies and in more 
antibody drug conjugates (aDcs) can deliver potent drugs to cancer cells by employing the specificity of monoclonal 
antibodies (mabs). aDcs have demonstrated significant anticancer activity and, in 2011, brentuximab vedotin has been 
approved by the FDa for the treatment of hodgkin’s and anaplastic large cell lymphomas. cD22 is an ideal target for aDc 
against B-cell malignancies because of its lineage-specific expression and rapid internalization upon antibody binding. 
In this study, we evaluated the anti-cD22 mab hB22.7 as a vehicle for the targeted delivery of the potent toxin saporin 
(sap). In vitro, hB22.7-sap was cytotoxic against a panel of non-hodgkin’s lymphoma (NhL) cell lines representing the 
most common types of the disease. Moreover, in a xenograft model of NhL, hB22.7-sap significantly inhibited the 
growth of established lesions and completely prevented tumor development when treatment was initiated within 24 h 
from tumor-cell inoculation. hB22.7-sap had no significant in vivo toxicity. In conclusion, hB22.7 constitutes a potential 
platform for cD22-targeted aDcs.
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than 90% of the most common types of NHL, namely, follicular 
and diffuse large B-cell lymphoma (DLBCL).5 One of the most 
appealing features of CD22 as a target for ADC therapy is that 
the binding of mAb facilitates its rapid internalization, in turn 
promoting the efficient delivery of conjugated drugs into target 
cells. In vitro studies with CD22+ human B-cell NHL have dem-
onstrated that within 15 min from the binding of an anti-CD22 
mAb, approximately 80% CD22 molecules are internalized.6
HB22.7 is an anti-CD22 mAb developed (and humanized) 
by our group for the treatment of NHL. HB22.7 is classified as 
a “ligand blocking” antibody because it binds to the same epit-
opes of CD22 as its natural ligands and effectively blocks bind-
ing.7 While in primary B cells HB22.7 induces a proliferative 
response, it activates apoptotic responses in neoplastic B cells, 
primarily through the stress activated protein kinase (SAPK) 
pathway.8 Using xenograft models of NHL, we have previously 
shown the lymphomacidal properties of HB22.7.9–13 In vivo stud-
ies demonstrated that HB22.7 is significantly more efficient than 
non-ligand blocking anti-CD22 mAbs.11 For the development of 
a CD22-targeted ADC, we hypothesized that it would be advan-
tageous to use HB22.7 because of its cytotoxic effect, which are 
not observed with other anti-CD22 mAbs. In the present study, 
we provide the “proof of principle” that HB22.7 is highly effi-
cient when used as a vehicle for the specific delivery of toxins, 
such as the plant-derived molecule saporin (SAP), to CD22+ 
NHL cell lines.
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independent cytotoxic effects in vitro, but only at concentrations 
higher than those used in this assay.8
To examine the impact of incubation time on HB22.7-SAP-
induced in vitro cytotoxicity, Raji cells were incubated with 
dilutions of HB22.7-SAP for 2 h, washed to remove unbound 
antibody, resuspended in fresh media and incubated for addi-
tional 70 h. Using these conditions, the IC
50
 of HB22.7-SAP 
increased approximately 5-fold to 22.2 ng/mL (data not shown).
In vivo efficacy and toxicity of HB22.7-SAP in an established 
NHL xenograft model. The antitumor activity of HB22.7-SAP 
was investigated with a xenograft model of NHL, in which tumors 
were allowed to reach a volume of 100–200 mm3 before treat-
ment initiation (designated as day 0). During the first two weeks 
of treatment, HB22.7-SAP (1 mg/kg) significantly inhibited 
(p < 0.01) tumor growth as compared with PBS and free HB22.7 
(0.6 mg/kg) plus free SAP (0.36 mg/kg) control groups (Fig. 3A). 
As measured on days 5 and 8, the average tumor volume of mice 
that received HB22.7-SAP was more than 2-fold smaller than that 
of mice that received PBS or free HB22.7 plus free SAP. Despite 
an initial control of tumor growth, however, by day 19 the average 
tumor volume of mice treated with HB22.7-SAP was no differ-
ent than that of control animals. It should be noted that the dose 
of HB22.7 used in “free HB22.7 plus free SAP” group was well 
below the dose that we previously used to inhibit tumor growth 
in a xenograft model of NHL.11 Thus, it was expected that free 
HB22.7 plus free SAP had no antitumor activity.
In the evaluation of HB22.7-SAP, body weight and complete 
blood counts (CBCs) were also assessed as indicators of treat-
ment-induced toxicity. Notably, HB22.7-SAP induced a slight 
weight loss, which could be completely recovered prior to the 
next injection (Fig. 3B). As a comparison, mice treated with PBS 
Results
HB22.7-SAP in vitro cytotoxicity. To ensure that SAP conjuga-
tion to HB22.7 did not affect CD22 binding, the CD22+ NHL 
cell lines Raji and Ramos were used to compare the binding of 
unmodified HB22.7 to that of HB22.7-SAP. SAP conjugation to 
HB22.7 had indeed no effect on its binding to CD22 (Fig. 1).
Using flow cytometry with HB22.7 as a probe, CD22 expres-
sion was assessed in cell lines representing the following types of 
NHL: Burkitt’s lymphoma (Ramos and Raji), transformed fol-
licular lymphoma (DOHH-2), mantle cell lymphoma (Granta 
519) and DLBCL (SU-DHL-4). All cell lines were CD22+, with 
Ramos and Raji exhibiting the highest levels of CD22 expres-
sion followed by Granta 519, DOHH-2 and SU-DHL-4 (Fig. 1). 
Jurkat T cells were used as a CD22− control. Accordingly, staining 
with HB22.7 did not result in a fluorescence signal higher than 
that obtained with FITC-conjugated anti-mouse control IgGs.
Next, the cytotoxicity of HB22.7-SAP against NHL cell lines 
in vitro was evaluated using an MTS assay. HB22.7-SAP exerted 
a potent cytotoxic effect against all CD22+ NHL cell lines with 
IC
50
 values ranging from 1 to 8.4 ng/mL (Fig. 2). Conversely, 
HB22.7-SAP exhibited no cytotoxicity against CD22− Jurkat 
cells. Further, an isotype-matched control ADC, mouse-IgG-
SAP, was not cytotoxic against any of the cell lines (data not 
shown). These data suggest that the in vitro cytotoxicity of 
HB22.7-SAP is dependent upon CD22 expression. As a control, 
the NHL cell lines were also treated with free HB22.7 plus free 
SAP at molar concentrations equivalent to those of each compo-
nent in the HB22.7-SAP conjugate. At all tested concentrations, 
free HB22.7 plus free SAP exerted no cytotoxicity (Fig. 2 and 
data not shown). It should be noted that free HB22.7 does have 
Figure 1. hB22.7-sap binding and assessment of cD22 expression by flow cytometry. The NhL cell lines Ramos, Raji, DOhh-2, Granta 519 and 
sU-DhL-4 were either left untreated (red), treated with anti-mouse IgG FITc (black) or hB22.7 plus anti-mouse IgG FITc (green). In some cases, cells 
were incubated with hB22.7-sap plus anti-mouse IgG FITc (blue). The T cell leukemia cell line Jurkat was used as a cD22− control.
internalization, release of free drug inside the target cell and sen-
sitivity of the target cell to the drug may play a role in the overall 
sensitivity of a particular cell type to ADCs.
To study the efficacy of HB22.7-SAP in vivo, we employed 
two xenograft models of NHL. In the first model, treatment 
was initiated when tumors reached a volume of 100–200 mm3. 
Using this model, mice treated with HB22.7-SAP experienced an 
inhibition of tumor growth for the first two weeks of treatment. 
However, mice eventually developed large, unresponsive tumors 
(Fig. 3A). In the second model, treatment was initiated 24 h after 
tumor cell implantation. The difference in treatment initiation 
had a significant impact on efficacy, as none of the mice treated 
with HB22.7-SAP in this second model developed tumors for the 
entire duration of the study (Fig. 4A). In previous studies with 
naked HB22.7, we reported similar findings that are consistent 
with the hypothesis that mAb-based therapeutics are more effec-
tive for the treatment of small tumors. Mice with tumors < 200 
mm3 at the time of HB22.7 treatment had a higher response rate 
and greater inhibition of tumor growth as compared with mice 
whose tumors were > 200 mm3 at the start of treatment.11
Unlike most other mAbs used in the construction of ADCs, 
HB22.7 has unique binding and functional characteristics that 
we surmise make it a superior platform for ADC-based thera-
peutics. Specifically, HB22.7 binds to the two NH
2
-terminal Ig 
domains of CD22 and blocks CD22 ligand binding. In neoplas-
tic B cells, this induces an apoptotic response and we have previ-
ously reported on the lymphomacidal properties of HB22.7 in 
xenograft models of NHL. On the contrary, anti-CD22 mAbs 
that do not block ligand binding have only modest functional 
effects. It remains unknown whether the efficacy of HB22.7-
SAP demonstrated in the current study is due in part to the 
direct cytotoxic effects of HB22.7 or solely due to the intracel-
lular delivery of the toxic payload. Certainly, using HB22.7 as 
the platform for the development of an ADC has theoretical 
advantages over other anti-CD22 mAbs that are not capable of 
or free HB22.7 plus free SAP gained 
weight over the same period of time. 
Additionally, the blood of mice from 
each treatment group was collected 
on days 6, 13 and 20 for CBCs. Mice 
treated with HB22.7-SAP had blood 
counts within the normal range and 
the counts did not fluctuate signifi-
cantly over time (Fig. 3C).
In vivo efficacy and toxicity of 
preemptive HB22.7-SAP treatment 
in a NHL xenograft model. To deter-
mine if the degree of tumor burden 
would affect HB22.7-SAP-mediated 
efficacy, a second NHL xenograft 
model was used. Twenty-four hours 
after subcutaneous implantation of 
Raji cells (designated as day 0), mice 
were started on the same treatment 
regimen mentioned above. Using 
the preemptive treatment model, 
HB22.7-SAP was highly effective, as no mice in this treatment 
group developed measureable tumors during the 50 d study 
period (Fig. 4A). On the contrary, free HB22.7 plus free SAP had 
no effect on tumor growth and mice from this group exhibited 
tumor volumes similar to mice treated with PBS.
Similar to the results obtained with the xenograft model 
described above (Fig. 3B), HB22.7-SAP induced a slight weight 
loss (8%) that could be recovered by the second injection 
(Fig. 4B). However, following the second and third injections, 
a moderate weight loss (13%) and a prolonged recovery period 
were observed.
Discussion
The goal of the present study was to demonstrate that the anti-
CD22 mAb HB22.7 can serve as a vehicle for the targeted delivery 
of a conjugated cytotoxic agent. To this end, as a proof-of-princi-
ple, we conjugated the plant-derived toxin, SAP to HB22.7 and 
showed that the resulting HB22.7-SAP conjugate has potent and 
specific antitumor activity in vitro and in vivo.
Using a panel of cell lines representing the major types of 
NHL, we demonstrated the potent in vitro cytotoxicity of 
HB22.7-SAP (Fig. 2). Interestingly, the expression of CD22 by 
the cell lines does not correlate well with HB22.7-SAP-induced 
cytotoxicity. For instance, Raji cells expressed 4 to 5-fold more 
CD22 molecules than DOHH-2 cells, yet DOHH-2 cells were 
almost 5-fold more sensitive to HB22.7-SAP. This phenomenon 
was previously documented by Polson et al. who showed that, 
among 18 NHL cell lines, CD22 receptor density do not cor-
relate well with cytotoxicity as induced by an anti-CD22-MC-
DM1 conjugate.14 Similarly, it has been previously shown that, 
in cases of low CD22 expression levels, such as by chronic lym-
phocytic leukemia (CLL) cells, CD22-targeted ADCs retain 
activity.15 The lack of correlation between CD22 expression and 
cytotoxicity suggests that factors such as the kinetics of receptor 
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Figure 2. In vitro cytotoxicity of hB22.7-sap against NhL cell lines. NhL cell lines were incubated with 
titrations of hB22.7-sap continuously for 72 h. The concentration of hB22.7-sap (ng/mL) corresponds 
to the final antibody concentration. cell viability was measured using an MTs assay and the mean of 3 
separate experiments performed in triplicate is shown. Jurkat T cells were used as a cD22− control cell 
line. additionally, Ramos cells were treated with free hB22.7 plus free sap at concentrations equivalent 
to those of each component of the hB22.7-sap conjugate.
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may be limited by issues stemming from the toxin itself. SAP 
is a plant-derived toxin and when injected into humans induces 
an immunogenic response in the form of antitoxin antibodies.25 
This leads to a rapid clearance of mAb-SAP conjugates and 
hence a reduction in the level of conjugate available for uptake 
by target cells. Additionally, the use of mAb-SAP conjugates 
in humans is limited by the possible development of a vascular 
leak syndrome and hepatotoxicity.26 Stirpe et al. showed that the 
non-specific uptake of a mAb-SAP conjugate by hepatocytes was 
most likely due to the SAP moiety of the conjugate rather than 
independent cytotoxicity. It should be noted that among CD22-
targeted ADCs that are currently in preclinical and clinical 
development (inotuzumab ozogamicin, moxetumomab pasudo-
tox and RG7593), none are based on an anti-CD22 mAb with 
documented independent cytotoxicity.14,16,17
Several groups have conjugated SAP to mAbs for targeted 
delivery to a variety of tumor cells and demonstrated signifi-
cant preclinical antitumor activity.18–23 In this study, SAP was 
chosen because of its potency and ease of chemical conjuga-
tion.24 However, clinical development of mAb-SAP conjugates 
Figure 3. In vivo efficacy and toxicity of hB22.7-sap. (A–C) To establish tumors, nude mice were subcutaneously injected with 5 × 106 Raji NhLcells. 
Tumors were allowed to grow until they reached a volume of 100–200 mm3 and this was designated as day 0. Mice were then randomly separated 
into three treatment groups (n = 8–10 per group) consisting of pBs, free hB22.7 (0.6 mg/kg) plus free sap (0.36 mg/kg) and hB22.7-sap (1 mg/kg). The 
dose of free hB22.7 and free sap was equivalent to each component in the hB22.7-sap conjugate. all treatments were administered by intreperitoneal 
injection weekly for a period of three weeks (indicated by arrows). (A) Tumor volume was calculated using the formula (L × W2)/2. (B) Body weight was 
measured twice a week and the percent of starting weight was calculated. (C) On days 6, 13 and 20, blood was collected from animals in each group 
(n = 3) for complete blood counts. *p < 0.01 compared with pBs and free hB22.7 plus free sap groups.
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In vivo efficacy and toxicity. Female athymic nude mice 
(6–8 weeks old) were obtained from Harlan Sprague–Dawley 
and maintained in micro-isolation cages under pathogen free 
conditions. All animal experiments were performed in compli-
ance with institutional guidelines and according to protocol 
No. 16322 approved by the Animal Use and Care Administrative 
Advisory Committee at the University of California, Davis. Mice 
were allowed to acclimatize for at least 4 d prior to the start of any 
experiment. Three days prior to tumor cell implantation, mice 
received 400 rads of whole body radiation. To establish tumors, 
5 × 106 Raji cells were resuspended in PBS and subcutaneously 
injected into the flank of each mouse. Tumors were allowed to 
grow until they reached a volume of 100–200 mm3 and this was 
designated as day 0. Mice were then randomly separated into 
3 treatment groups (n = 8–10 per group) consisting of PBS, free 
HB22.7 (0.6 mg/kg) plus free SAP (0.36 mg/kg) and HB22.7-
SAP (1 mg/kg). The doses of free HB22.7 and free SAP were 
equivalent to each component in the HB22.7-SAP conjugate. All 
the antigen-binding sites, carbohydrate moieties or Fc region of 
the mAb.27 As an alternative, potent small molecule drugs such 
as those from the auristatin (MMAE) and maytansine (DM1) 
families have shown promising results as cytotoxic components 
for ADCs. These drugs have similar potency as SAP but have 
the consistent advantage of not producing any of the above men-
tioned side-effects.
ADCs represent novel targeted therapeutics capable of 
simultanesouly improving the efficacy and reducing the toxic-
ity of drugs that are too potent to be administered systemically. 
HB22.7 is an ideal candidate as the platform for ADC because 
it targets an internalizing antigen expressed on neoplastic B cells 
and because of its unique functional characteristics not observed 
with other anti-CD22 mAbs.
Materials and Methods
HB22.7 and saponin. The anti-CD22 mAb HB22.7 was pre-
pared and characterized as described previously.8 SAP, mouse-
IgG-SAP and the custom conjugate, HB22.7-SAP, were produced 
by Advanced Targeting Systems.
Cell lines. Ramos, Raji, Granta 519 NHL and Jurkat T cells 
were purchased from the American Type Culture Collection. 
SU-DHL-4 and DOHH-2 NHL cells were purchased from the 
Deutsche Sammlung von Mikroorganismen und Zellkulturen 
(DSMZ). All cell lines were maintained with RPMI 1640 
medium supplemented with 10% fetal bovine serum (FBS) and 
incubated at 37°C, 5% CO
2
 and 90% humidity.
Flow cytometry. To assess CD22 expression, 0.5 × 106 
cells per sample were resuspended in 100 μL FACS buffer 
(PBS + 0.5% FBS) and chilled on ice. HB22.7 (10 μg/mL) was 
incubated with cells for 30 min on ice, followed by 3 washes with 
ice cold FACS buffer. Cells were then incubated with a 1/50 dilu-
tion of goat anti-mouse IgG-FITC (Invitrogen) for 30 min on ice 
and in the dark. Cells were washed 3 times and 10,000 events 
were analyzed on a FACScan (BD Biosciences).
MTS assays. The in vitro cytotoxicity of HB22.7-SAP was 
evaluated using an MTS assay.28 Cells were seeded in 96-well 
plates at a density of 1 × 104 cells/well in 90 μL media. HB22.7-
SAP was serially diluted with media and 10 μL of each dilution 
was added to the appropriate well and incubated continuously 
for 72 h. As a control, another group of cells was treated with 
free HB22.7 plus free SAP at molar concentrations equivalent 
to each component in the HB22.7-SAP conjugate. In a sepa-
rate experiment, Raji cells were incubated with HB22.7-SAP for 
2 h, washed 3 times, resuspended in fresh media and cultured 
for an additional 70 h. After a 72 h incubation, the cell viabil-
ity of all treatment groups was assessed using the CellTiter 96 
Aqueous One Solution Cell Proliferation Assay according to the 
manufacturer’s instructions. MTS solution (20 μL) was added to 
each well and allowed to incubate for 1 h at 37°C. Cell viability 
as a percent of the untreated control was calculated as follows: 
[(OD
490
 treated − OD
490
 background) / (OD
490
 control − OD
490
 
background) × 100]. The mean ± standard deviation (SD) of 3 
separate experiments performed in triplicate is shown.
Figure 4. In vivo efficacy of preemptive hB22.7-sap treatment. 
(A and B) Nude mice were subcutaneously injected with 5 × 106 Raji 
cells. Twenty-four h later, designated as day 0, mice were randomly 
separated into three treatment groups (n = 8–10 per group) consisting 
of pBs, free hB22.7 (0.6 mg/kg) plus free sap (0.36 mg/kg) and hB22.7-
sap (1 mg/kg). The dose of free hB22.7 and free sap was equivalent to 
those of each component in the hB22.7-sap conjugate. starting on day 
0, treatments were administered by intraperitoneal injection weekly for 
a period of three weeks (indicated by arrows). (A) Tumor volume was 
calculated using the formula (L × W2)/2. (B) Body weight was measured 
twice a week and the percent of starting weight was calculated.
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and collected into EDTA-lined tubes for complete blood counts 
(CBCs).
Statistical analysis. Statistical analysis was performed by 
Student’s t-tests for two groups, and one-way ANOVA for mul-
tiple groups. All results were expressed as the mean ± standard 
error (SEM) unless otherwise noted. p values < 0.05 were con-
sidered statistically significant. Survival analysis was performed 
using GraphPad Prism 4 software.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
This work was supported by the Schwedler Family Foundation 
and the deLeuze Non-toxic Cure for Lymphoma Fund, and by 
Department of Defense grant W81XWH-10-1-0716.
treatments were administered weekly for three weeks by intra-
peritoneal injection. Tumor volume was measured using digital 
calipers and calculated by the formula (L × W2)/2, where L is the 
longest and W is the shortest in tumor diameters (mm).
To assess the significance of starting tumor volume on 
HB22.7-SAP-mediated tumor growth inhibition, we used a 
second xenograft model in which treatment was initiated 24 h 
following tumor cell implantation (designated as day 0). Mice 
(n = 8–10 per group) were separated into treatment groups as 
mentioned above and treated using the same doses and dosing 
regimen.
Body weight and other symptoms and signs of toxicity 
(unkempt fur, ataxia, piloerection) were observed daily. Mice 
were sacrificed when tumor volume exceeded 1500 mm3 or 
20 mm in diameter. On days 6, 13 and 20, blood was drawn 
from the lateral saphenous vein of animals in each group (n = 3) 
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